ABT-384
ABT-384 是 11β-羟基类固醇脱氢酶 1 (HSD-1) 的有效选择性抑制剂，该酶可在多种组织中再生皮质醇。
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | ABT-384 |
|---|---|
| Iupac 化学名称 | 4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide |
| 同义词 | ABT-384 ; ABT 384 ; ABT384 ; |
| 英文同义词 | ABT-384 ; ABT 384 ; ABT384 ; |
| 分子式 | C25H34F3N5O2 |
| 分子量 | 493.56 |
| Smile | O=C(C12CC3C(NC(C(N4CCN(C5=NC=C(C(F)(F)F)C=C5)CC4)(C)C)=O)C(C2)CC(C3)C1)N |
| InChiKey | CLHMYBJIOZXCEX-UHFFFAOYSA-N |
| InChi | InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35) |
| Cas号 | 868623-40-9 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 类白色固体 |
|---|---|
| 纯度 | ≧98.0% |
| 存储 | 0-4 ℃ 可短期保存（两周）；- 20 ℃ 可长期保存。 |
| 可溶性 | 溶于DMSO |
| 处理方式 | Refer to MSDS operation |
| 运输条件 | 可在室温下运输。 |
| 海关编码 | 2934200090 |
| Targets | selective 11-β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: An G, Liu W, Dutta S. Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384. J Clin Pharmacol. 2015 Oct;55(10):1079-85. doi: 10.1002/jcph.531. Review. PubMed PMID: 25931139.
2: An G, Liu W, Katz DA, Marek GJ, Awni W, Dutta S. Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. Biopharm Drug Dispos. 2014 Oct;35(7):417-29. doi: 10.1002/bdd.1912. PubMed PMID: 25041811.
3: Marek GJ, Katz DA, Meier A, Greco N 4th, Zhang W, Liu W, Lenz RA. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. Alzheimers Dement. 2014 Oct;10(5 Suppl):S364-73. doi: 10.1016/j.jalz.2013.09.010. PubMed PMID: 24418055.
4: Katz DA, Liu W, Locke C, Jacobson P, Barnes DM, Basu R, An G, Rieser MJ, Daszkowski D, Groves F, Heneghan G, Shah A, Gevorkyan H, Jhee SS, Ereshefsky L, Marek GJ. Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384. Transl Psychiatry. 2013 Aug 27;3:e295. doi: 10.1038/tp.2013.67. PubMed PMID: 23982627; PubMed Central PMCID: PMC3756293.
5: Liu W, Katz DA, Locke C, Daszkowski D, Wang Y, Rieser MJ, Awni W, Marek GJ, Dutta S. Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly Adults. Clin Pharmacol Drug Dev. 2013 Apr;2(2):133-51. doi: 10.1002/cpdd.5. PubMed PMID: 27121668.
6: An G, Liu W, Katz DA, Marek G, Awni W, Dutta S. Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos. 2013 May;41(5):1035-45. doi: 10.1124/dmd.112.049742. PubMed PMID: 23431112.
